ArticleScientific reports2025
Effects of ATF2/TSC1 on epilepsy by modulating the microphages polarization of microglia.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- HMC3 revealed: how much do these "Microglia" really tell us?Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Epilepsy (EP) is a chronic nervous system disease characterized by recurrent attacks, and its causes are complicated. Inflammatory reaction mediated by microglia is an important factor in the progression of EP. Activating transcription factor 2 (ATF2) can be used as a transcription factor to regulate the microglia-mediated inflammatory response, but its role in EP is unclear. In this study, kainic acid (KA) was used to induce the EP cell and mouse model. Real-time polymerase chain reaction was used to detect ATF2, TNF-α, IL-6, TGF-β, and IL-10 mRNA expression. ATF2, INOS, ARG1, and TSC1 protein levels was examined by western blot. The fluorescence intensity of ATF2, IBA1, CD80, and CD206 was examined by immunofluorescence staining. The cell ratios of CD80, IL-1β, CD206, and CD63 were detected by flow cytometry. Dual-luciferase reporter and chromatin immunoprecipitation assays were conducted to verify the interaction between ATF2 and TSC1. Hematoxylin & eosin and Nissl staining were used to observe the structure of hippocampus and Nissl bodies. The results indicated that KA induced M1 polarization of HMC3 cells and increased the levels of TNF-α and IL-6 mRNA by activating KA receptors, and inhibiting KA receptors attenuated the M1 polarization of KA-induced HMC3 cells. ATF2 expression was increased in KA-induced HMC3 cells and hippocampal tissues of mouse, while TSC1 expression was repressed. ATF2 knockdown diminished the M1 polarization of KA-induced HMC3 cells, enhanced the M2 polarization, and relieved neuroinflammation in EP mouse. TSC1 overexpression inhibited M1 polarization in KA-induced HMC3 cells. Dual luciferase and chromatin immunoprecipitation results revealed that ATF2 bound to the promoter of TSC1 and negatively regulated the transcription of TSC1. In conclusion, inhibition of ATF2 and promotion of TSC1 transcription may be a new pathophysiological mechanism for the treatment of EP neuroinflammation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.